Home › Nausea and Vomiting › NCT07446439
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
The Thetis Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Tradipitant on Nausea and Vomiting After GLP-1R Agonist Administration in Healthy Overweight or Obese Volunteers
Who can join
Ages 18 to 65 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Body Mass Index ≥ 25 and \< 40 kg/m\^2 * No serious medical problems or chronic diseases, specifically no type I or type II diabetes Exclusion Criteria: * Another disorder that contributes to gastrointestinal symptoms * History of intolerance and/or hypersensitivity to NK-1 receptor antagonists * History of intolerance and/or hypersensitivity to GLP-1 receptor agonists * Exposure to any investigational medication within the past 60 days
About the study
The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.
What is being tested
- Tradipitant (drug)
- Placebo (drug)
Sponsor: Vanda Pharmaceuticals · Participants: 280 · Started: Mar 27, 2026
Contact the study team
- Vanda Pharmaceuticals · Phone: (202) 734-3400
Official record on ClinicalTrials.gov — NCT07446439
Locations in the U.S.
| California | Vanda Investigational Site, Los Angeles Vanda Investigational Site, San Diego Vanda Investigational Site, San Jose (Not yet recruiting) |
| Florida | Vanda Investigational Site, Tampa |
| New Jersey | Vanda Investigational Site, Hamilton (Not yet recruiting) |
| New York | Vanda Investigational Site, New York (Not yet recruiting) Vanda Investigational Site, Syosset (Not yet recruiting) |
| Texas | Vanda Investigational Site, Plano (Not yet recruiting) Vanda Investigational Site, San Antonio (Not yet recruiting) |
| Virginia | Vanda Investigational Site, Burke (Not yet recruiting) |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.